Condition

NK Cell clinical trials and research

As of November 12, 2026, Find a Trial lists 3 NK Cell clinical trials that are recruiting, at sites in 2 countries (most in China (2), United States (1)). By phase: Phase 1 (3). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.

Newest NK Cell clinical trials

StudyPhaseWhereStatusRegistered
Engineered NK Cells with dual CARs for recurrent glioblastoma Phase 1 Houston, Texas Recruiting May 12, 2026
Immunotherapy using modified NK cells for treating relapsed or refractory AML Phase 1 Beijing, China Recruiting Feb 19, 2025
Donor NK Cell Infusion with Low-Dose IL-2 for AML relapse after stem cell transplant Phase 1 Beijing, Beijing Municipality Recruiting Oct 15, 2024

All recruiting trials (3)

Related topics

Acute Myeloid Leukemia (AML)AML (Acute Myelogenous Leukemia)Phase 1Recurrent Glioblastoma

Quick answers

How many NK Cell clinical trials are recruiting right now?

3, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in China (2 trials), United States (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 3. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →

Last reviewed 2026-11-12 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.